Download
s12935-018-0565-4.pdf 3,42MB
WeightNameValue
1000 Titel
  • Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs
1000 Autor/in
  1. Haas, Bodo |
  2. Klinger, Veronika |
  3. Keksel, Christina |
  4. Bonigut, Verena |
  5. Kiefer, Daniela |
  6. Caspers, Julia |
  7. Walther, Julia |
  8. Wos-Maganga, Maria |
  9. Weickhardt, Sandra |
  10. Röhn, Gabriele |
  11. Timmer, Marco |
  12. Frötschl, Roland |
  13. Eckstein, Niels |
1000 Erscheinungsjahr 2018
1000 Art der Datei
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2018-05-04
1000 Erschienen in
1000 Quellenangabe
  • 18:69
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2018
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12935-018-0565-4 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935937/ |
1000 Ergänzendes Material
  • https://cancerci.biomedcentral.com/articles/10.1186/s12935-018-0565-4#Declarations |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Intrinsic chemoresistance of glioblastoma (GBM) is frequently owed to activation of the PI3K and MEK/ERK pathways. These signaling cascades are tightly interconnected however the quantitative contribution of both to intrinsic resistance is still not clear. Here, we aimed at determining the activation status of these pathways in human GBM biopsies and cells and investigating the quantitative impact of both pathways to chemoresistance. METHODS: Receptor tyrosine kinase (RTK) pathways in temozolomide (TMZ) treatment naive or TMZ resistant human GBM biopsies and GBM cells were investigated by proteome profiling and immunoblotting of a subset of proteins. Resistance to drugs and RTK pathway inhibitors was assessed by MTT assays. Apoptotic rates were determined by Annexin V staining and DNA damage with comet assays and immunoblotting. RESULTS: We analyzed activation of RTK pathways by proteome profiling of tumor samples of patients which were diagnosed a secondary GBM and underwent surgery and patients which underwent a second surgery after TMZ treatment due to recurrence of the tumor. We observed substantial activation of the PI3K and MEK/ERK pathways in both groups. However, AKT and CREB phosphorylation was reduced in biopsies of resistant tumors while ERK phosphorylation remained unchanged. Subsequent proteome profiling revealed that multiple RTKs and downstream targets are also activated in three GBM cell lines. We then systematically describe a mechanism of resistance of GBM cell lines and human primary GBM cells to the alkylating drugs TMZ and cisplatin. No specific inhibitor of the upstream RTKs sensitized cells to drug treatment. In contrast, we were able to restore sensitivity to TMZ and cisplatin by inhibiting PI3K in all cell lines and in human primary GBM cells. Interestingly, an opposite effect was observed when we inhibited the MEK/ERK signaling cascade with two different inhibitors. CONCLUSION: Temozolomide treatment naive and TMZ resistant GBM biopsies show a distinct activation pattern of the MEK/ERK and PI3K signaling cascades indicating a role of these pathways in resistance development. Both pathways are also activated in GBM cell lines, however, only the PI3K pathway seems to play a crucial role in resistance to alkylating agents and might serve as drug target for chemosensitization.
1000 Sacherschließung
lokal PI3K
lokal Glioblastoma
lokal Temozolomide
lokal Drug resistance
lokal Cisplatin
1000 Fachgruppe
  1. Medizin |
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. http://orcid.org/0000-0002-1213-3527|https://frl.publisso.de/adhoc/creator/S2xpbmdlciwgVmVyb25pa2E=|https://frl.publisso.de/adhoc/creator/S2Vrc2VsLCBDaHJpc3RpbmE=|https://frl.publisso.de/adhoc/creator/Qm9uaWd1dCwgVmVyZW5h|https://frl.publisso.de/adhoc/creator/S2llZmVyLCBEYW5pZWxh|https://frl.publisso.de/adhoc/creator/Q2FzcGVycywgSnVsaWE=|https://frl.publisso.de/adhoc/creator/V2FsdGhlciwgSnVsaWE=|https://frl.publisso.de/adhoc/creator/V29zLU1hZ2FuZ2EsIE1hcmlh|https://frl.publisso.de/adhoc/creator/V2VpY2toYXJkdCwgU2FuZHJh|https://frl.publisso.de/adhoc/creator/UsO2aG4sIEdhYnJpZWxl|https://frl.publisso.de/adhoc/creator/VGltbWVyLCBNYXJjbw==|https://frl.publisso.de/adhoc/creator/RnLDtnRzY2hsLCBSb2xhbmQ=|https://frl.publisso.de/adhoc/creator/RWNrc3RlaW4sIE5pZWxz
1000 Label
1000 Förderer
  1. Federal Institute for Drugs and Medical Devices (BfArM)
  2. University of Applied Sciences Kaiserslautern
1000 Fördernummer
  1. -
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6408149.rdf
1000 Erstellt am 2018-05-30T07:44:42.752+0200
1000 Erstellt von 281
1000 beschreibt frl:6408149
1000 Bearbeitet von 122
1000 Zuletzt bearbeitet Fri Jan 31 00:08:17 CET 2020
1000 Objekt bearb. Mon Jun 04 09:52:35 CEST 2018
1000 Vgl. frl:6408149
1000 Oai Id
  1. oai:frl.publisso.de:frl:6408149 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source